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ABSTRACT
Accumulation of extracellular matrix derived fromglomerularmesangial cells is an early feature of diabetic
nephropathy. Ca2+ signals mediated by store–operated Ca2+ channels regulate protein production in a
variety of cell types. The aim of this study was to determine the effect of store–operated Ca2+ channels in
mesangial cells on extracellular matrix protein expression. In cultured humanmesangial cells, activation of
store–operated Ca2+ channels by thapsigargin signiﬁcantly decreased ﬁbronectin protein expression and
collagen IV mRNA expression in a dose-dependent manner. Conversely, inhibition of the channels by
2-aminoethyl diphenylborinate signiﬁcantly increased the expression of ﬁbronectin and collagen IV.
Similarly, overexpression of stromal interacting molecule 1 reduced, but knockdown of calcium release–
activated calcium channel protein 1 (Orai1) increased ﬁbronectin protein expression. Furthermore,
2-aminoethyl diphenylborinate signiﬁcantly augmented angiotensin II–induced ﬁbronectin protein ex-
pression, whereas thapsigargin abrogated high glucose– and TGF-b1–stimulated matrix protein expres-
sion. In vivo knockdown of Orai1 in mesangial cells of mice using a targeted nanoparticle siRNA delivery
system resulted in increased expression of glomerular ﬁbronectin and collagen IV, and mice showed sig-
niﬁcant mesangial expansion compared with controls. Similarly, in vivo knockdown of stromal interacting
molecule 1 in mesangial cells by recombinant adeno–associated virus–encoded shRNAmarkedly increased
collagen IVprotein expression in renal cortex and causedmesangial expansion in rats. These results suggest
that store–operated Ca2+ channels in mesangial cells negatively regulate extracellular matrix protein ex-
pression in the kidney, which may serve as an endogenous renoprotective mechanism in diabetes.
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Diabetic nephropathy (DN) is the most common
cause of ESRD.1,2One of early features ofDN includes
accumulation of extracellular matrix (ECM) proteins
in glomerular mesangium.3,4 This pathologic change
in glomerulus may, with time, progress to glomer-
ulosclerosis and ultimately, irreversible ESRD.5,6
Overproduction of ECM, including ﬁbronectin and
collagen IV (Col IV), by glomerular mesangial cells
(MCs) anddeposition of these proteins tomesangium
are important contributors tomesangial expansion in
the early stage of DN.7–9 Therefore, suppression of
ECMproduction inMCsmay be a therapeutic option
to protect kidney from diabetic damages.
MCs sit between glomerular capillary loops and
play important roles in mesangial matrix homeo-
stasis.7,10,11 MC dysfunction is closely associated
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with several kidney diseases, including DN.12,13 Like many
other cell types, MC function is controlled by intracellular
Ca2+ signals.11,14 In this regard, store–operated Ca2+ channel
(SOC) plays a pivotal role in many physiologic processes in
MCs.14 SOC is activated on depletion of the endoplasmic re-
ticulum (ER) in response to activation of G protein–coupled
receptors.15 Two proteins, STIM116,17 and Orai1,18–20 have
been identiﬁed as required components of the SOC pathway.
STIM1 is located in the ER membrane and functions as an ER
Ca2+ sensor, whereas Orai1 is located in the plasma membrane
and functions as a Ca2+ channel.21,22 Over the past decades, we
and others have shown that SOC mediates MC Ca2+ responses
to a variety of circulating and locally produced hormones.23–27
We have also shown that STIM1 was required for activation of
SOC in human MCs.28 Recently, we found that the SOC path-
way was enhanced in humanMCs with prolonged high glucose
treatment.29 However, the role of SOC in MCs in the develop-
ment ofDN is completely unknown. In this study, we used both
in vitro and in vivo systems and tested a hy-
pothesis that SOC in MCs regulated ECM
protein expression.
RESULTS
SOC Suppressed ECM Protein and
mRNA Expression in Human MCs
Treatment of cultured human MCs with 1
mM thapsigargin (TG), a classic and widely
used activator of SOC,15 for 2 days signiﬁ-
cantly reduced ﬁbronectin protein expres-
sion (Figure 1, A and D). This inhibitory
effect was abolished by GSK-7975A, a selec-
tive SOC inhibitor.30–33 Consistently, inhi-
bition of SOC with 50 mM 2-aminoethyl
diphenylborinate (2-APB) but not its vehicle
control (methanol) signiﬁcantly increased
ﬁbronectin protein expression (Figure 1,
B and E). The 2-APB response was also
observed for Col IV, another matrix pro-
tein (Figure 1, C and F). Furthermore, ac-
tivation of SOC by TG reduced expression
of Col IV mRNA in a dose-dependent
manner (Figure 1G). These data suggest
that SOC negatively regulates ECM ex-
pression at both mRNA and protein levels
in MCs.
Overexpression of STIM1 Decreased
but Knockdown of Orai1 Increased
Fibronectin Expression in Human MCs
STIM1 is an ER membrane protein that
gates SOC by interacting with the channel
protein, Orai1.16,17,21,22 We expressed
STIM1 in MCs by transfecting the cells
with YFP-tagged human STIM1 expression plasmid
(pDS_XB_YFP-STIM1-II).17 As shown by the data in Figure
2, with increased STIM1 expression (YFP-STIM1), ﬁbronec-
tin was correspondingly decreased. Cotransfection of the ex-
pression plasmid with an shRNA construct against human
STIM1 (YFP-STIM1+shSTIM1) not only reversed a high ex-
pression of STIM1 but prevented a decrease in ﬁbronectin
protein expression as well. Consistent with the Western blot
data, immunoﬂuorescence staining showed that ﬁbronectin
signals were reduced in MCs transfected with YFP-STIM1
compared with YFP (alone)-transfected MCs (control). Im-
portantly, the ﬁbronectin signals were also much weaker than
those in the neighboring negatively transfected cells (Figure
2D). Furthermore, knocking down Orai1, the pore-forming
subunit of SOC, using previously characterized synthetic
siRNA29 signiﬁcantly increased ﬁbronectin expression (Figure
2, E and F). These data further support an inhibitory effect of
SOC on ECM protein expression.
Figure 1. SOC suppressed ECM protein and mRNA expression in cultured human
MCs. (A–C) Representative Western blots showing (A) activation of SOC on ﬁbronectin
(FN), (B) inhibition of SOC on FN, and (C) inhibition of SOC on Col IV expressions.
TG was 1 mM. GSK, GSK-7975A (10 mM); Meth, methanol (vehicle control for 2-APB;
50 mM); TB, tubulin; UT, untreated cell. Both actin and TB were used as a loading
control. Serum-starved cells (in 0.5% FBS) were with or without treatments for 2 days
before harvested. (D–F) Summary data corresponding to experiments presented in
A–C, respectively. *P,0.05 compared with the other two groups. (G) Quantitative
real–time RT-PCR showing effects of different doses of TG on Col IV mRNA expres-
sion. Cells were treated with TG for 24 hours in 0.5% FBS medium (0 represents
DMSO control). Expression levels of Col IV mRNA at different doses of TG treatment
were normalized to those in MCs without treatment (UT). *P,0.05 compared with UT
and TG at 0 and 1 nM groups; †P,0.05 compared with TG at the 10 nM group.
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SOC Limited Ang II–Induced Fibronectin Expression in
Human MCs
Ang II is a ﬁbrotic factor that stimulates ECM protein
production in DN.5,34–38 Ang II signaling in MCs involves
several types of Ca2+-conductive channels. These include
voltage–operated Ca2+ channel (VOC), receptor–operated Ca2+
channel (ROC), and SOC.11,14,24,29,39–41 We then examined
effects of different channel blockers on Ang II–induced ﬁbro-
nectin expression in human MCs. As shown by the data in
Figure 3, Ang II treatment (100 nM for 2 days) markedly in-
creased ﬁbronectin expression level. This response was signif-
icantly attenuated by nifedipine (1 mM), a selective inhibitor
of VOC, but was not affected by SKF96365 (10 mM), an in-
hibitor to ROC/TRPC channels. Importantly, 2-APB (50mM)
that selectively inhibits SOC at a concen-
tration .10 mM15,42,43 potentiated the
Ang II effect, although it did not reach sta-
tistical signiﬁcance. These data suggest that
Ang II–activated Ca2+ channels function
distinctly in regulation of ECM protein ex-
pression. VOCmediates Ang II–stimulated
ﬁbronectin expression, whereas SOC may
attenuate its ﬁbrotic response.
Activation of SOC Inhibited High
Glucose–Induced ECM Protein
Expression in MCs
High glucose is a pathogenic stimulator for
ECM expression inMCs during the progress
of DN.5,9,44–47 We examined if activation of
SOC could inhibit high glucose–induced ﬁ-
brotic response. As shown in Figure 4, high
glucose treatment signiﬁcantly increased ex-
pression levels of both ﬁbronectin and Col
IVproteins. The high glucose responseswere
signiﬁcantly abolished by TG but not by its
vehicle. Furthermore, TG treatment reduced
ﬁbronectin and Col IV expression to a level
lower than that in untreated MCs (NG in
Figure 4), although it did not reach a statis-
tically signiﬁcant level. These data suggest a
beneﬁcial role of SOC in diabetic kidney.
Activation of SOC Inhibited TGF-b1–
Stimulated Fibronectin Expression in
MCs
It has been ﬁrmly established that TGF-b
signaling plays the most crucial role in glo-
merular matrix accumulation in DN.5,47
We next studied if SOC regulated the
TGF-b1 pathway, As expected, TGF-b1
but not its vehicle control (HCl) dramati-
cally increased ﬁbronectin protein expres-
sion. Activation of SOC by TG signiﬁcantly
abolished the TGF-b1 response (Figure 5).
These data indicate that suppression of TGF-b1 signaling may
be one mechanism for the antiﬁbrotic effect of SOC.
In Vivo Knockdown of Orai1 in MCs Increased ECM
Protein Expression in Renal Cortex and Glomerulus
and Induced Mesangial Expansion in Mice
Orai1 is the pore-forming unit of SOC.21,22We speculated that
we could inhibit SOC function in MCs in vivo by delivery of
siRNAs against Orai1 to intact animals. We have previously
shown speciﬁc delivery of approximately 75 nm PEGylated
gold nanoparticles (NPs) into MCs in mouse kidney.48 We
have also previously shown that approximately 75 nm cyclo-
dextrin–containing polycation (CDP) –containing NPs carry-
ing siRNA (siRNA-CDP-NPs) accumulate in the glomerulus49
Figure 2. Expression of STIM1 decreased and knockdown of Orai1 increased ﬁbro-
nectin (FN) expression in human MCs. (A) Representative Western blot showing FN
expression in human MCs without transfection (UTran) and cells transfected with YFP
construct or YFP–tagged human STIM1 expression plasmid (YFP-STIM1) or co-
transfected with YFP-STIM1 with shRNA against human STIM1 (YFP-STIM1+shRNA).
Actin was used as a loading control. (B and C) Summary data from the experiments
presented in A showing (B) STIM1 and (C) FN expression levels in MCs with different
treatments by normalized to actin. *P,0.05 compared with all other groups. (D) Im-
munoﬂuorescence staining showing ﬁbronectin expression (red signals) in human
MCs transfected with either YFP (green signals in upper panels) or YFP–tagged STIM1
expression plasmid (YFP-STIM1; green signals in lower panels). The YFP- or YFP-
STIM1–transfected cells are outlined with dashed lines. Experiments were performed
2 days after transfection. Images were representative of at least three independent
experiments. Original magniﬁcation 3200. (E) Representative Western blot showing
FN expression in human MCs UTran and the cells transfected with scramble control
siRNA (Scr) or siRNA against human Orai1 (siOrai1). a-Tubulin (TB) was used as
a loading control. (F) Summary data from the experiments presented in E. FN ex-
pression level in each group was normalized to TB, and the values in each group were
further normalized to the those of the UTran group. *P,0.05 compared with both the
UTran and the Scr groups.
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and that these siRNA-CDP-NPs can be used for the selective
delivery of functional siRNA to mouse MC in vivo.50 In this
study, we formulated the siRNA-CDP-NPs with Cy3-tagged
siRNA against mouse Orai1 (NP-Cy3-siOrai1) and injected
these siRNA-CDP-NPs into mice through
the tail vein. Consistent with our previous
reports,48 the siRNA-CDP-NP complexes
were accumulated in glomeruli, with scarce
distribution in other regions (Figure 6A).
Western blot of renal cortex extracts veri-
ﬁed the efﬁciency of knocking down Orai1
(Figure 6B). To conﬁrm delivery of siRNA-
CDP-NPs to the MCs, we counterstained
kidney sections from mice that received
Cy3-siRNA containing NP with the MC
marker thymic antigen 1 using the OX-7
antibody and the podocyte marker synap-
topodin protein using antisynaptopodin
antibody. We found persistent Cy3-siRNA
ﬂuorescent signal after administration of
the siRNA-CDP-NPs that highly colocalized
with the OX-7 but not synaptopodin anti-
body staining (Figure 6C). Semiquantitative
colocalization analysis revealed 85% OX-7
staining colocalizationwith Cy3 ﬂuorescence
and 90% colocalization of Cy3-siRNA ﬂuo-
rescence with OX-7 staining (Figure 6D).
However, both values of colocalization of
Cy3-siRNA ﬂuorescence with synaptopodin
staining were minimal (Figure 6D). These
data show that siRNA-CDP-NPs were pre-
dominantly deposited in glomerular MCs.
We then conducted Western blot and
found that abundance of ﬁbronectin protein
in the renal cortexwas signiﬁcantly increased
in the mice treated with siRNA-CDP-NPs
carrying Cy3-siOrai1 (Figure 7, A and B).
Consistently, additional immunohisto-
chemical examinations showed remarkable
increases in both ﬁbronectin and Col IV
staining in the glomeruli of mice receiving
siRNA-CDP-NPs (Figure 7, C and D). In
agreement with those changes, the mice
treated with siRNA-CDP-NPs carrying
Cy3-siOrai1 showed signiﬁcant expansion
ofmesangium (Figure 8, A and B). However,
glomerular volume in Orai1–knocked down
mice only had the tendency to increase but
no statistical signiﬁcance.
In Vivo Knockdown of STIM1 in MCs
Increased Col IV Protein Expression in
Renal Cortex and Induced Mesangial
Expansion in Rats
The inhibition of SOC onmesangial matrix
expression in intact animals was further examined in rats. We
chose recombinant adeno–associated virus (rAAV) to deliver
shRNA against rat STIM1 to rat kidney, because the in vivo
rAAV/shRNA delivery system has been well developed in
Figure 3. SOC suppressed Ang II–induced ﬁbronectin (FN) expression in human
MCs. (A) Representative Western blot showing FN expression in human MCs with-
out treatment (UT) or treated with Ang II (100 nM), Ang II plus nifedipine (1 mM; Ang
II+Nif), Ang II plus 2-APB (30 mM; Ang II+2-APB), or Ang II plus SKF96365 (10 mM;
Ang II+SKF). Actin was used as a loading control. MCs were with and without various
treatments for 2 days in 0.5% FBS medium. (B) Summary data from the experiments
presented in A. FN expression levels were normalized to actin. *P,0.05 compared
with the group as indicated (paired t test).
Figure 4. SOC inhibited high glucose (HG)-stimulated ECM protein expression in human
MCs. (A and B) Representative Western blots showing (A) ﬁbronectin (FN) and (B) Col IV
expression inMCs cultured in normal glucose (NG, 5.6mMglucose+20mMmannitol) or HG
(25 mM glucose) in the absence or presence of DMSO (1:1000; vehicle control) and TG
(1 mM). Tubulin (TB) was used as a loading control. MCs were with and without various
treatments for (A) 2 or (B) 3 days in 0.5% FBS medium. (C and D) Summary data from the
experiments presented in A and B, respectively. FN and Col IV expression levels were
normalized to tubulin. *P,0.05 compared with NG group; †P,0.05 compared with both
HG and HG+DMSO groups.
4 Journal of the American Society of Nephrology J Am Soc Nephrol 26: ccc–ccc, 2015
BASIC RESEARCH www.jasn.org
rats.51–54 The rAAV–carried eGFP–tagged shRNA against rat
STIM1 (rAAV-eGFP-shStim1) was administered to rats by tail
vein injection. An rAAV1/2 encoding an eGFP–tagged scram-
bled shRNA served as a control. Rats were euthanized 8 weeks
after injection. Although the rAAV-eGFP-shRNAwas distrib-
uted in both glomerulus and tubule regions (Figure 9A), there
was good colocalization of rAAV-eGFP-shSTIM1 signals with
OX-7 staining (Figure 9B), suggesting that MCs had good in-
fection with the virus. Western blot veriﬁed a reduction of
STIM1 protein in the renal cortex from the rats treated with
rAAV-eGFP-shSTIM1 (Figure 9C). Corresponding to a low
expression of STIM1 protein, Col IVexpression level was dra-
matically increased in the renal cortex of the rAAV-eGFP-
shSTIM1 rats compared with rAAV-Con rats (Figure 9D).
Like the mice with knockdown of Orai1, the rats with knock-
down of STIM1 showed signiﬁcant mesangial expansion (Fig-
ure 9, E and F). In addition, the rAAV-eGFP-shSTIM1 rats
manifested tubular hypertrophy, probably because of knock-
down of STIM1 in tubular epithelial cells. Furthermore, the
rats receiving rAAV-eGFP-shSTIM1 had a signiﬁcantly greater
urinary albumin excretion rate, an indication of renal injury
(Figure 9G). In summary, these data from rats suggest a reno-
protective effect of the endogenous SOC in the kidney.
DISCUSSION
Diabetes is the leading cause of ESRD worldwide. The early
changes in diabetic kidney include accumulation of ECM
proteins in the glomerulus, which ultimately progresses to
glomeruloscleorosis and irreversible ESRD. There is no cura-
tive therapy currently available for DN. Despite the increased
use of antihypertensive medications and rennin-angiotensin
system (RAS) inhibitors in patients withDN, the improvement
of renal function is slight.55 Therefore, new
therapeutic approaches are needed. This
study provides in vitro and in vivo evidence
that SOC in MCs inhibits glomerular ma-
trix protein expression. Thus, SOC in MCs
could be a protective mechanism in dia-
betic kidneys. Theoretically, selective en-
hancement of the renoprotective SOC
function and any component in its signal-
ing pathway would be expected to amelio-
rate renal damage in diabetes and limit the
development of DN.
Our previous study showed that the
abundance of STIM1/Orai1 proteins (es-
sential components of SOC pathway) was
increased in the glomerulus by diabetes and
MCs by high glucose.29 This paradoxical
phenomenon suggests that, in addition to
well known deleterious processes, diabetes
simultaneously activates a beneﬁcial SOC
pathway in MCs as a compensatory mech-
anism to counteract detrimental pathways generated in dia-
betic kidneys. For instance, the Ang II system is signiﬁcantly
enhanced and contributes to mesangial expansion and glo-
merular ﬁbrosis through ﬁbrogenic mechanisms in diabetic
kidney.35–37 However, Ang II can activate Gq–coupled recep-
tor signaling and thus, activates the matrix-inhibitory
SOC.39,56,57 Conceivably, if SOC is suppressed, the Ang II–
induced matrix protein expression would be augmented be-
cause of loss of an antagonistic action from SOC. The dual
effects of Ang II in diabetic kidney may explain the modest
effect of RAS inhibitors on delaying progression of DN, be-
cause the inhibitors suppress both detrimental and beneﬁcial
effects of Ang II and thereby, compromise their therapeutic
efﬁciency.
SOC function is distinct in different tissues and cell types.15,58
In general, the SOC–associated signaling pathway promotes
protein synthesis and cell growth,15 for instance, contributing
to cardiac hypertrophy.51,59 However, a recent study revealed
that the SOC–mediated Ca2+ inﬂux suppressed cell growth in
mouse embryonic ﬁbroblasts and rat uterine leiomyoma cells
through inhibition of AKT1.60 Thus, the effect of SOC on pro-
tein production might be cell type speciﬁc and/or cell context
dependent. Our data suggest that SOC–mediated Ca2+ sig-
naling in glomerular MCs negatively regulates ECM protein
expression. A similar example is the regulation of protein se-
cretion by Ca2+ in juxtaglomerular (JG) cells. Like MCs, JG
cells are modiﬁed smooth muscle cells that synthesize, store,
and release renin into the blood stream for initiating the RAS
system. Usually, Ca2+ signal through SOC stimulates protein
secretion in granular cells.15 In contrast, activation of SOC in
JG cells inhibits renin secretion.61
MCs express several type of Ca2+-conductive channels.14
Our study suggests that inhibition of ECM protein expression
is SOC speciﬁc, because blockade of VOC and ROC
Figure 5. Activation of SOC inhibited TGF-b1–stimulated ﬁbronectin (FN) protein
expression in human MCs. (A) Representative Western blots showing FN expression in
MCs without treatment (UT) or treated with HCl (4 mM; vehicle control for TGF-b1) or
TGF-b1 (5 ng/ml) in the presence of DMSO (1:1000; vehicle control of TG) or TG (1
mM). All treatments were 15 hour with 0.5% FBS medium. Tubulin (TB) served as
a loading control. (B) Summary data from the experiments presented in A. FN ex-
pression level was normalized to tubulin. *P,0.05 compared with both UT and HCl
groups; †P,0.05 compared with both TGF-b1 and TGF-b1+DMSO groups.
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signiﬁcantly attenuated and did not affect the Ang II–induced
matrix protein expression in cultured MCs, respectively. Pre-
vious studies by us and others showed that VOC and ROC can
regulate contractile function of MCs.14,40,62,63 Differential
functions of distinct Ca2+ channels in the same cell might be
caused by channel type–speciﬁc downstream pathways. For
instance, in MCs, the intermediators that regulate ECM pro-
tein expression may be functionally linked or physically adja-
cent to SOC. Thus, the local Ca2+ signals delimited to the
SOC–associated Ca2+ microdomains can be sensed by these
molecules and subsequently, inhibit ECM protein expression.
Although the mechanism for SOC inhibiting ECM protein
expression in MCs is not fully elucidated in this study,
inhibition on TGF-b1 signaling might be involved. However,
in addition to the TGF-b1/Smad pathway,3,4,47,64–67 many
molecules and multiple pathways, such as Ang II,35–37 reactive
oxygen species,3,9,68 mitogen–activated protein kinase,3,47,69
and protein kinase C,3,47,70 are involved in accumulation of
ECM in DN. It is possible that the SOC–
mediated Ca2+ signals modulate one or
more of those pathways, leading to sup-
pression of ECM expression.
Here, we used the siRNA-CDP-NP de-
livery system and an rAAV delivery system
to introduce RNAi sequences into MCs in
mice and rats, respectively. This approach is
built on the anatomic properties of glo-
merular capillary. The glomerular capillary
walls have 70–100 nm endothelial fenestra-
tions. The surrounded glomerular base-
ment membrane generates a size-selective
barrier with a pore size of 4 nm. MCs di-
rectly adjoin the endothelium without in-
tervening the basement membrane.7,71
Thus, particles in the size of 4–100 nm
can permeate through the fenestrated glo-
merular capillary wall and yet, be restricted
in passing through the glomerular base-
ment membrane, and therefore, they
come into the mesangial region under a
high transmural pressure gradient. Shimizu
et al.71 have successfullydeliverednanocarriers
containing siRNA in the 10- to 20-nm-size
range to MCs in animals. We used a sim-
ilar approach using approximately 75 nm
siRNA-CDP-NPs that have been shown
to accumulate within the glomeruli of
mice.49 In agreement with those studies,
the siRNA-CDP-NPs in this study were
predominantly localized in MCs, with
very limited distribution in the extra-
glomerular region and glomerular podo-
cytes. Both mouse and human MCs could
rapidly internalize the siRNA-NPs in vitro
(data not shown). Therefore, the decrease
in Orai1 protein expression in renal cortex was most likely
caused by knockdown of Orai1 in MCs. We further reason
that the increases in ﬁbronectin and Col IVexpression in renal
cortex and glomerulus and glomerular mesangial expansion
were attributed to reduced Orai1 protein (i.e., inhibition of
SOC) in MCs.
One advantage of rAAV vectors is that they can efﬁciently
transfer genes of interest to a target tissue or organ, leading to
high levels of stable and long-term expression after a single
application.72–76 Although our viral particles were in a size of
approximately 20 nm, the rAAV/shRNA complex was not as
selective to MCs as siRNA-CDP-NPs. In addition to MCs, re-
nal tubules and other glomerular cell types were also infected
by the virus. Hence, the increase in Col IV expression, mes-
angial expansion, and renal injury (increase in albumin-to-
creatinine ratio) in the rAAV/shSTIM1-treated rats might be
partially attributed to a decreased STIM1 protein (i.e., inhibi-
tion of SOC) in MCs. Whether and how much a reduction of
Figure 6. NP-Cy3-siOrai1 was predominantly localized in MCs in mouse kidney. (A)
Representative images from three mice showing localization of NP-Cy3-siOrai1 (red) in
glomeruli (indicated by arrows) but not in tubules. Original magniﬁcation 3200. (B)
Representative Western blot of renal cortex extracts from three independent experi-
ments showing Orai1 expression in the mouse with injection of NP control (NP-Con)
and NP-Cy3-siOrai1. Although the predicted size of Orai1 is approximately 33 kD, the
antibody actually detects a band at approximately 50 kD. L, protein ladder; tubulin,
loading control. (C) Localization of NP-Cy3-siOrai1 in MCs (upper panels) and podo-
cytes (POD; lower panels) representative of three mice. MCs were stained with OX-7
(green), and podocytes were stained with synaptopodin (green). NP-Cy3-siOrai1 was
shown as red signals. Original magniﬁcation 3200. (D) Semiquantiﬁcation of the co-
localizations of MC and podocyte markers with NP-Cy3-simOrai1 shown in C using
BioimageXD software.
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STIM1 in other type of cells contributed to the increase in
glomerular matrix are unclear in this study.
In summary, this study strongly suggests a beneﬁcial effect of
SOC in MCs by inhibiting ECM protein expression, which may
protect the kidney from diabetic injury at early stages of DN.
Thus, SOC could be a promising therapeutic option to limit
progress of DN. Furthermore, MCs do not have a cell type–
speciﬁc promoter, and thereby, it is impossible to genetically
manipulate an MC–speciﬁc gene expression. We have shown
in this study that the nanocarriers of a particular size can be
used asMC–speciﬁc siRNAdelivery systemsby systemic injection.
Because the siRNA-CDP-NPs system has been used as a research
tool as well as a human therapeutic48,71,77,78 and because MC
injury is associated with many renal diseases,7,10 systemic admin-
istration of MC-selective siRNA-CDP-NPs targeting a particular
protein may have a potential for the treatment of renal diseases.
CONCISE METHODS
Animals
All procedures were approved by the University
of North Texas Health Science Center
(UNTHSC) Institutional Animal Care and Use
Committee. In total, 9 male Sprague–Dawley
rats and 10 male C57BL/6 mice were used in
this study. All rats and mice were between 2 and
4 months of age. Rats were purchased from
Harlan (Indianapolis, IN), andmicewere purchased
from Charles River Laboratories (Wilmington,
MA). All animals were maintained at the animal
facility of UNTHSC under local and National In-
stitutes of Health guidelines.
In Vivo Delivery of NPs into the
Kidney of Mice
The targeted NP delivery system was used to
deliver siRNA against Orai1 to the kidneys of
mice. Mice were randomly divided into control
and Orai1–knocked down groups (ﬁve mice in
each group). The mice in the Orai1–knocked
down group were given NPs containing Cy3-
tagged siRNA against mouse Orai1 (NP-Cy3-
siOrai1) by tail vein injection at a dose of 10
mg/kg siRNA in an approximately 100-ml injec-
tion volume. Themice in the control groupwere
only given NPs through the same route in the
same injection volume. Mice in both groups re-
ceived the intravenous injections on days 1 and 3
of the experiment and were euthanized on day 5
for kidney harvesting.
In Vivo Delivery of rAAVs into the
Kidney of Rats
rAAVsofserotype1/2(rAVE;GeneDetect,Sarasota,
FL) were used to deliver shRNA constructs to rat
kidneys. Ratswere randomlydivided into control
and STIM1–knocked down groups (three rats each group). The rats in
STIM1–knocked down group were injected with rAAV1/2 encoding
eGFP-tagged shRNA against rat STIM1 (rAAV-eGFP-shStim1)
through the tail vein at 1.531010 genomic particles in approximately
0.3 mL. The target gene sequence of the shRNAwas published in ref.
79. In the control group, rats were injected with rAAV1/2 encoding an
eGFP–tagged scrambled shRNA at the same concentration of virus in
the same injection volume. Rats were euthanized 8 weeks after injec-
tion for kidney harvesting. In Figure 9, E and F, three rats without virus
treatment were used as controls.
siRNA-CDP-NP Formulation
siRNANPs were formed by using CDP and adamantine-polyethylene
glycol as previously described (precomplexation).80 NPs were formed
in 5% glucose in deionized water (D5W) at a charge ratio of 36 and
an siRNA concentration of 2 mg/ml. The Cy3–labeled siRNA oligos
Figure 7. In vivo knockdown of Orai1 in MCs increased glomerular ECM protein
expression in mice. (A and B) Western blot of renal cortex extracts showing ex-
pressions of ﬁbronectin (FN) protein in the cortex of kidney from the mice treated with
control NP (NP-Con) and NP-Cy3-siOrai1 (knockdown of Orai1). TB, a-tubulin
(a loading control). (A) Representative blot. (B) Summary data. *P,0.05 compared with
NP-Con. (C and D) Immunohistochemistry showing expressions of (C) FN and (D) Col
IV in the glomeruli of the mice treated with NP-Con and NP-Cys-siOrai1. Both FN and
Col IV are shown as green staining. In NP-Con, a bright-ﬁeld image was captured to
show the glomerulus. In NP-Cy3-siOrai1, the distribution of NP-Cy3-siOrai1 is in-
dicated by Cy3 signals (red). Arrows indicate glomeruli. Original magniﬁcation 3200.
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targeting mouse Orai1 were purchased from Integrated DNA Tech-
nologies, Inc. (Chicago, IL). The sense strand sequence is 59-/5Cy3/
GGGUUGCUCAUCGUCUUUAGUGC-39.
Immunoﬂuorescence Histochemistry
Rats and mice were euthanized by intraperitoneal injection of
pentobarbital (100 mg/kg body wt) at indicated time points. After
washing out blood with PBS, the left kidneys were removed and ﬁxed
in 4% paraformaldehyde in PBS overnight. Formalin-ﬁxed organs
were dehydrated and embedded in molten parafﬁn to generate
sections of 4 mm in thickness (Cryostat 2800 Frigocut-E; Leica In-
struments). Anti–OX-7mousemAb at 1:100 and Alexa Fluor 488 (for
mice) or 568 (for rats) goat anti-mouse IgG (Invitrogen, Grand
Island, NY) at 1:2000 were used to label glomerular MCs. Sections
were examined using an Olympus microscope (BX41) equipped for
epiﬂuorescence and anOlympusDP70 digital camerawithDPmanager
software (version 2.2.1). Images were converted to 16-bit format and
uniformly adjusted for brightness and contrast using ImageJ (version
1.47; NIH). Semiquantiﬁcation of colocalizations of NP-Cy3-siOrai1
with the MC or podocyte marker (Figure 6D) was examined using
BioimageXD software.
Assessment of Mesangial Area and
Glomerular Volume
Four-micrometer parafﬁn–embedded kidney
sections were stained with periodic acid–Schiff
(Sigma-Aldrich, St. Louis, MO). Images were
captured using an Olympus DP70 digital
camera with DP manager software (version
2.2.1) and traced using ImageJ software (ver-
sion 1.47; NIH). Glomerular areawasmeasured
by tracing around the perimeter of the glomeru-
lar tuft. Mesangial area was deﬁned as the periodic
acid–Schiff-positive and nuclei-free area in the
mesangium and expressed as a ratio to a total
glomerular area. Glomerular volume was esti-
mated using the formula V=(4A/3)(A/p)1/2,
where A is area, and V is volume.
Extraction of Renal Cortical Proteins
Right kidneys were removed from rats or mice
immediately after euthanasia. Renal cortex was
separated from the other region of the kidney
using a sharp blade, and the cortical tissue was
minced using two sharp blades. The cortical
tissues were sonicated in a lysis buffer followed
by centrifugation at 20,8173g for 15 minutes at
4°C. The supernatants were collected for West-
ern blot.
Cell Culture and Transfection
Human MCs were purchased from Lonza
(Walkersville, MD). Cells were cultured in DMEM
medium (Gibco, Carlsbad, CA) supplemented
with 25 mM Hepes, 4 mM glutamine, 1.0 mM
sodium pyruvate, 0.1 mM nonessential amino
acids, 100 units/ml penicillin, 100 mg/ml streptomycin, and 20%
FBS. Cells ,10 generations were used in this study.
All transfections in this study were transient transfections
using LipofectAmine and Plus Reagent (Invitrogen-BRL, Carlsbad,
CA) following the protocols providedby themanufacturer. Experiments
were conducted approximately 48 hours after transfection.
Immunoﬂuorescence Cytochemistry
Human MCs were transfected with either YFP alone or YFP–tagged
STIM1 expression plasmid. Immunoﬂuorescence staining was per-
formed 2 days after transfection using the protocol described in our
previous publication.81 The cells were incubated with ﬁbronectin
primary antibody at 1:50 in PBS plus 10% donkey serum and 0.2%
Triton X-100 at 4°C overnight. The secondary antibody was goat anti-
rabbit IgG conjugated with Alexa Fluor 568 (Invitrogen) at a concen-
tration of 1:500 for 1 hour at room temperature. Fluorescent staining
was examined using an Olympus microscope (BX41) equipped for
epiﬂuorescence and an Olympus DP70 digital camera with DP man-
ager software (version 2.2.1). Images were converted to 16-bit format
and uniformly adjusted for brightness and contrast using ImageJ
(version 1.47; NIH).
Figure 8. In vivo knockdown of Orai1 in MCs induced mesangial expansion in mice.
(A) Representative periodic acid–Schiff staining showing mesangial matrix expansion
in the glomeruli from mice treated with NP alone (NP-Con) or NP-siRNA-Orai1 (NP-
Cy3-siOrai1). Original magniﬁcation 3200. (B and C) Summary data from 81 glomeruli
(n=81) from ﬁve to seven sections per kidney per mouse of ﬁve mice showing glo-
merular mesangial area and glomerular volume. *P,0.05.
8 Journal of the American Society of Nephrology J Am Soc Nephrol 26: ccc–ccc, 2015
BASIC RESEARCH www.jasn.org
Western Blots
Whole-cell lysates or renal cortical extracts were fractionated by 10%
SDS-PAGE, transferred to PVDF membranes, and probed with
primary ﬁbronectin, Col IV, b-actin, a-tubulin, STIM1, and Orai1
antibodies. Bound antibodies were visualized with Super Signal West
Pico or Femto Luminol/Enhancer Solution (Thermo Fisher Scien-
tiﬁc, Rockford, IL). The speciﬁc protein bands were visualized and
captured using an AlphaEase FC Imaging System (Alpha Innotech,
San Leandro, CA). The integrated density value of each band was
measured by drawing a rectangle outlining the band using AlphaEase
FC software with autobackground subtraction. The expression levels
of targeted proteins were quantiﬁed by normalization of the inte-
grated density values of those protein bands to that of the actin or
tubulin band on the same blot.
Quantitative Real-Time RT-PCR
As described in our previous publication,29 brieﬂy, the total RNAwas
isolated from cultured human MCs using a PerfectPure RNA
Figure 9. In vivo knockdown of STIM1 in MCs increased ECM protein expression in renal cortex and induced mesangial expansion in
rats. STIM1 was knocked down using shRNA against rat STIM1 (shSTIM1). The shSTIM1 construct was tagged with eGFP and packaged
into rAAV (rAAV-eGFP-shSTIM1). Rats were euthanized 8 weeks after injection of rAAV-eGFP-shSTIM1 and control rAAV (rAAV-Con).
(A) Distribution of rAAV-eGFP-shSTIM1 (green signals) in rat kidney representative of three rats. Kidney was ﬁxed with 4% PFA. Original
magniﬁcation 3200. (B) Enlarged images from the red-dashed box in A showing localization of rAAV-eGFP-shSTIM1 in MCs. MCs were
stained with OX-7 (red); rAAV-eGFP-shSTIM1 is shown as green signals. Original magniﬁcation 3200. (C) Western blot of fresh renal
cortex extracts from the rats with injection of rAAV-Con and rAAV-eGFP-shSTIM1. The blots represents two repeats from the same
samples. Actin is a loading control. L, protein ladder. (D) Western blot of fresh renal cortex extracts showing Col IV expression in renal
cortex of the rats treated with rAAV-Con and rAAV-eGFP-shSTIM1. The blot is representative of three independent experiments (three
rats). TB, tubulin (a loading control). (E) Representative periodic acid–Schiff staining of kidney sections from a rat without administration
of rAAV (untreated) and a rat treated with rAAV-eGFP-shSTIM1. The rat with administration of rAAV-eGFP-shSTIM1 showed marked
mesangial expansion and tubular hypertrophy. Original magniﬁcation 3200. (F) Summary data. The numbers of glomeruli from ﬁve to
seven sections per kidney per rat from three untreated rats and two rAAV-eGFP-shSTIM1–treated rats are indicated. **P,0.01 (un-
treated versus rAAV-eGFP-shSTIM1). (G) Urinary albumin-to-creatinine ratio (ACR) in rAAV-Con and rAAV-eGFP-shSTIM1 rats (8 weeks
after injection). *P,0.05.
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Cultured Cell Kit (5 Prime, Inc., Hamburg, Germany) following the
manufacturer’s protocol. Human Col IV primers (forward: CAGC-
CAGACCATTCAGATCC; reverse: TGGCGCACTTCTAAACTCCT)
and b-actin primers (forward: ACTGTGTGGATTACATGGGC-
CAGA; reverse: AGGATTGCCTCCACAATCCGTACA) were synthe-
sized by IDT (Coralville, IA). The Col IV levels were normalized by
b-actin mRNA. Quantiﬁcation was calculated as follows: mRNA
levels =2DCt, where DCt=Ct,Col IV2Ct,actin.
Materials
TG, nifedipine, SKF96365, 2-APB, rabbit polyclonal antiﬁbronectin,
b-actin and a-tubulin antibodies, methanol, and DMSO were pur-
chased from Sigma-Aldrich. GSK-7975A was kindly donated by
GlaxoSmithKline (Brentford, UK). GOK/STIM1 mouse mAb was
purchased from BD Biosciences Pharmingen (San Jose, CA). Anti-
Orai1 and anti-CD90/thymic antigen 1 (MRC OX-7) antibodies were
purchased from Abcam, Inc. (Cambridge, MA). Mouse anti-Col IV
mAb was purchased from Meridian Life Science, Inc. (Memphis, TN).
YFP-STIM expression plasmid (pDS_XB_YFP-STIM1-II) was a gift
from Tobias Meyer (Stanford University School of Medicine Stanford,
CA). This plasmid was originally characterized in ref. 17. The shRNA
construct that targets on human STIM1 (shSTIM1) was generated in
our laboratory using GeneClip U1 Hairpin Cloning System-hMGFP
(Promega). This construct has been used in our previous study.28
Statistical Analyses
Data were reported as means6SEMs. The one-way ANOVA plus
Newman–Keuls post hoc analysis and unpaired t test were used to
analyze the differences among multiple groups and between two
groups, respectively, unless indicated in individual ﬁgures. P,0.05
was considered statistically signiﬁcant. Statistical analysis was per-
formed using SigmaStat (Jandel Scientiﬁc, San Rafael, CA).
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